The U.S. FDA has granted accelerated approval to the first KRAS inhibitor, along with two companion diagnostics, for certain patients with KRAS-mutated lung cancer. The U.S. Food and Drug Administration (FDA) granted accelerated approval...
The FDA has granted accelerated approval to a molecularly targeted therapeutic along with a companion diagnostic to treat certain patients with cholangiocarcinoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to...
The FDA granted accelerated approval to the first targeted therapeutic and a companion diagnostic for certain adult patients with non-small cell lung cancer that tests positive for specific mutations in a protein that helps...
The FDA has approved an immunotherapeutic for certain patients with these cancers who had their cancer completely resected and received chemoradiotherapy before surgery. The U.S. Food and Drug Administration (FDA) approved the immunotherapeutic nivolumab...
The FDA has granted accelerated approval to an immunotherapeutic to be used in combination with a targeted therapeutic and chemotherapy to treat certain patients with gastric or gastroesophageal junction adenocarcinomas. The U.S. Food and...
The FDA has approved the targeted therapeutic loncastuximab tesirine-lpyl to treat certain adult patients with large B-cell lymphoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta) to...
The FDA has granted accelerated approval to an immunotherapy to treat certain adult patients with endometrial cancer that tests positive for a specific biomarker. The U.S. Food and Drug Administration (FDA) has granted accelerated...
The FDA has approved an immunotherapeutic in combination with chemotherapy to treat certain patients with gastric cancer, gastroesophageal junction cancer, and a common form of esophageal cancer. The U.S. Food and Drug Administration (FDA)...
The FDA granted accelerated approval to the targeted therapeutic sacituzumab govitecan to treat certain patients with the most common form of bladder cancer. The U.S. Food and Drug Administration (FDA) recently granted accelerated approval...
The FDA approved the first CAR T-cell therapy to treat certain adult patients with multiple myeloma. The U.S. Food and Drug Administration (FDA) has approved idecabtagene vicleucel (Abecma) to treat adult patients with relapsed...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More